Modafinil: the unique properties of a new stimulant.
Modafinil, a novel stimulant which has several remarkable features that distinguish it from other stimulants, has been developed by Lafon, a French pharmaceutical company. Unlike the amphetamines, for example, modafinil is reported to have minimal peripheral side effects at therapeutic doses. It also appears to have a low abuse potential, does not interfere with normal sleep, and does not seem to produce tolerance. It improves vigilance especially in sleep-deprived subjects. It has been used clinically for up to 3 years in the treatment of narcolepsy and idiopathic hypersomnia. It could be an ideal replacement for amphetamine in short-term operations in which fatigue might threaten the successful completion of a mission. We recommend that military laboratories experienced in studying sustained performance include modafinil or perhaps a more selective alpha 1 receptor agonist in their investigations.
Headquarters USAF Human Systems Division, Brooks Air Force Base, TX 78235.
T J
TJ
Lyons
J
J
French
D000818:Animals; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077408:Modafinil; D012893:Sleep Wake Disorders / Q000188:drug therapy
D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D000077408:Modafinil